The FDA’s Circulatory System Devices Panel recommended that the cardiac resynchronization therapy defibrillator (CRT-D), developed by Boston Scientific, be approved for use in patients with mild heart failure in the United States. If the device is approved by the FDA, nearly 4 million more Americans could be candidates for treatment with the CRT-D.
Science Brief thanks to EurekAlert.
Read more here:
Rochester-led study leads to recommendation for use of heart failure treatment nationwide
Net News Publisher for Science News
Related articles by Zemanta
- Chemists Influence Stem-cell Development with Geometry (netnewspublisher.com)
- Food And Drug Administration Seeks Permanent Injunction Against Louisiana Sprout Grower (netnewspublisher.com)
- Conventional Infection Control Measures Found Effective in Reducing MRSA Rates (netnewspublisher.com)
